SCHEMBL941963

SCHEMBL941963

CCCCCC(CC)c1ccsc1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.46
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
ALOX5 P09917 1/20 0.33
SLC2A1 P11166 2/20 0.32
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32
CA2 P00918 2/20 0.31
CSNK1E P49674 1/20 0.31
IDO1 P14902 1/20 0.31
TDO2 P48775 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14516277 0.95 NR1I2 (0.41) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL18965267 0.91 NR1I2 (0.41) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL22166101 0.91 NR1I2 (0.41) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL18885123 0.91 NR1I2 (0.41) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL19788245 0.91 NR1I2 (0.41) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL28774586 0.91 NR1I2 (0.41) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL27408998 0.89 NR1I2 (0.40) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL20760340 0.88 NR1I2 (0.39) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL13848615 0.87 CHRNB2 (0.36) NR1I2CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL16432014 0.84 NR1I2 (0.35) NR1I2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10980816-B2 Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof SANOFI (FR) 2021-04-20 US disclosed
US-20200323874-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2020-10-15 US disclosed
EP-3192792-A1 AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Vigonvita Life Sciences Co., Ltd. (CN) 2017-07-19 EP disclosed
US-20110001905-A1 TRANSPARENT THIN-FILM ELECTRODE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-06 US disclosed
EP-0793900-B1 FABRICATION OF AN ELECTROLUMINESCENT DEVICE FORSKARPATENT I LINKOEPING AB (SE) 2001-10-04 EP disclosed
US-5932965-A Electroluminescent device and a method for fabricating an electroluminescent device FORSKARPATENT I LINKOPING AB (SE) 1999-08-03 US disclosed
EP-0793900-A1 ELECTROLUMINESCENT DEVICE AND A WAY TO FABRICATE IT Forskarpatent i Linköping AB (SE) 1997-09-10 EP disclosed
WO-1996003015-A1 ELECTROLUMINESCENT DEVICE AND A WAY TO FABRICATE IT FORSKARPATENT I LINKÖPING AB (SE) 1996-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200323874-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF DPYD, TYMP, DHFR NR1I2 828/4885CHRNB2 3893/4885CHRNB4 4569/4885
US-10980816-B2 Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof DPYD, TYMP, DHFR NR1I2 846/4885CHRNB2 4073/4885CHRNB4 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.